Pulmonary Arterial Hypertension Market - By Drug Class (Prostacyclin And Prostacyclin Analogs, Soluble Guanylate Cyclase Stimulators, Endothelin Receptor Antagonist, Phosphodiesterase 5, Vasodilators), By Route of Administration & Forecast, 2021-2027
Published Date: August - 2024 | Publisher: MIR | No of Pages: 240 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationPulmonary Arterial Hypertension Market Size
Pulmonary Arterial Hypertension (PAH) Market size exceeded USD 6.6 billion in 2020 and is anticipated to grow at a CAGR of 6% between 2021 and 2027. The strong product pipeline and novel drug combination awaiting approval are expected to boost the market growth. Furthermore, pulmonary arterial hypertension is a rare lung disorder that is commonly reported in children. The high proportion of children suffering from untreated PAH offers immense market expansion opportunities and is poised to promote the use of pulmonary arterial hypertension drugs.
While vasodilators are commonly used to treat PAH, they come with a downsideside effects. These can include everything from racing heart and swelling to palpitations and chest pain. Because these side effects can be a concern for patients with chronic conditions, the U.S. FDA keeps a close eye on the use of vasodilators. Not only that, but PAH drugs that target high blood pressure and widen blood vessels need to prove they're both safe and effective before they can hit the market. They need the green light from the FDA before they can be sold, which is a complex process that takes time. So, all these side effects and regulatory hurdles could hold back the growth of the PAH drug market over the next few years.
The market for treating pulmonary arterial hypertension saw a minor hit during the COVID-19 pandemic, and its effects may linger a bit. Early on in 2020, the pandemic's impact on the industry was strongest. Patients with pulmonary arterial hypertension faced higher risks of severe COVID-19. Other challenges, like delays in diagnosis testing, shifting hospital care policies, and disruptions in the supply chain for medications, also slowed down the industry's growth. But the pandemic also highlighted the crucial role of PAH medications. As more PAH patients were hospitalized with COVID-19, the demand for these treatments grew.
| Report Attribute | Details |
|---|---|
| Base Year | 2020 |
| Pulmonary Arterial Hypertension Market Size in 2020 | 6,632.9 Million (USD) |
| Forecast Period | 2021 to 2027 |
| Forecast Period 2021 to 2027 CAGR | 6.0% |
| 2027 Value Projection | 10,132.5 Million (USD) |
| Historical Data for | 2016 to 2020 |
| No. of Pages | 120 |
| Tables, Charts & Figures | 143 |
| Segments covered | Drug Class, Route of Administration, and Region |
| Growth Drivers |
|
| Pitfalls & Challenges |
|
Rising geriatric population globally will stimulate the industry progression
Rising geriatric population base in developing countries is positively influencing the market value. According to the United Nations report, in 2020, the aging population accounted for around 727 million people aged 65 years or above worldwide. This number is projected to grow in the coming decades by two-fold, reaching over 1.5 billion by 2050. As per the United Nations Population Fund and HelpAge India statistics, the number of elderly adults in India will reach to 173 million by 2026. Thus, with the significant proportion of population aging, the frequency of PAH in the elderly population will increase in the foreseeable future. Rising age is one of the non-modifiable factors that surges the risk related to PAH. Additionally, the elderly population base is prone to this disease due to diastolic dysfunction and age-associated blood vessel stiffening that further augments the business demand.
Several educational and awareness programs are initiated by market players and the government to increase the awareness level for PAH in healthcare providers and patients. These programs further prove beneficial for the elderly population base as it raises the awareness level amongst them. Several government organizations such as the WHO, Million Hearts, and others have undertaken certain initiatives to create awareness that accelerates the business revenue.
Pulmonary Arterial Hypertension Market Analysis
The endothelin receptor antagonist segment is predicted to witness 5.5% growth rate through 2027 owing to the rising demand for endothelin receptor antagonist drugs. These drugs are widely recommended as a targeted therapy to reverse the damage of the heart & lungs, slow the progression of PAH, and dilate blood vessels among others. The clinical studies have confirmed that patient with pulmonary arterial hypertension produces high amount of endothelin that often leads to high blood pressure. Thus, an endothelin receptor antagonist is highly prescribed by physicians to reduce the amount of endothelin present in the blood vessels. Moreover, progressive investments for research and development of endothelin receptor antagonist will promote the segment growth. Recently there has been a rapid expansion in research targeting endothelin receptor that has other therapeutic advantages, mainly in the treatment of pulmonary arterial hypertension.
The oral segment in the pulmonary arterial hypertension market dominated more than 69% of the revenue share in 2020 led by the oral route of administration that offers a broad range of dosage forms such as tablets, capsules, and solutions among others. The oral route is the most preferred route for drug administration attributed to its benefits including the convenience of drug administration, patient compliance, and non-invasiveness. Oral therapies increase patient safety and comfort at an affordable cost. Furthermore, rapid delivery of drugs, a higher rate of bioavailability, and high efficacy among others will propel the segment revenue.
U.S. dominated the North America pulmonary arterial hypertension market and will reach USD 6.25 billion by 2027 driven by the numerous factors such as the availability of a high number of board-certified physicians, growing hospital admissions related to PAH, and growing supportive government initiatives among others. The prevalence of PAH is increasing in the country attributed to the risk factors comprising smoking, HIV, sedentary lifestyle, and alcohol consumption among others. In addition, in the U.S., the Orphan Drug Act (ODA) was introduced in 1983 to provide incentives for industry investment in treatments for PAH.
In Europe, Germany market held 10% of revenue share in 2020 and is predicted to cross USD 194 million by 2027 on account of the increase in the prevalence of pulmonary arterial hypertension, optimal health workforce, and facilitative government initiatives to improve the health of patients suffering from PAH in the country. As per the article published by the National Center for Biotechnology Information, in 2016, left heart disease is one of the common factors causing PAH that affected around 1.3 million people in Germany. According to the article published in 2020, over 5.6 million health workers were working in Germany. A large health workforce highlights well-developed healthcare infrastructure in the country. The German health care system covers over 80% of the medical costs of its residents is assisting the patients to avail the quality of treatment for pulmonary arterial hypertension.
Pulmonary Arterial Hypertension Market Share
Some of the major companies operating in the market are
- Bayer AG
- Eli Lilly and Company
- Gilead Sciences, Inc.
- GlaxoSmithKline plc
- Johnson & Johnson
These major participants are adopting strategic formulations such as new product development & commercialization, commercial expansion, distribution agreements for business expansion. Moreover, these leaders are investing heavily in developing products, thereby fuelling the revenue generation.
Pulmonary arterial hypertension market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2016 to 2027, for the following segments
Click here to Buy Section of this Report
Market, By Drug Class, 2016 - 2027 (USD Million)
- Prostacyclin And Prostacyclin Analogs
- Soluble Guanylate Cyclase (SGC) Stimulators
- Endothelin Receptor Antagonist (ERA)
- Phosphodiesterase 5 (PDE-5)
- Vasodilators
- Others
Market, By Route of Administration, 2016 - 2027 (USD Million)
- Oral
- Intravenous
- Inhalation
The above information is provided for the following regions and countries
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Latin America
- Brazil
- Mexico
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Related Reports
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy